1. Show article details.

    Synergy Pharmaceuticals Appoints Timothy Callahan and Richard Daly to Board of Directors

    Business Wire – 6:00 AM ET 07/01/2015

    Synergy Pharmaceuticals Inc. (SGYP) today announced that it has appointed Timothy Callahan and Richard Daly as new independent directors to its board. This Smart News Release features multimedia.

  2. Show article details.

    Synergy Pharmaceuticals to Present at the Cantor Fitzgerald Healthcare Conference

    Business Wire – 6:00 AM ET 06/30/2015

    Synergy Pharmaceuticals Inc. (SGYP) today announced that its Chairman and Chief Executive Officer, Gary S. Jacob, Ph.D., will present a corporate update at the Cantor Fitzgerald Healthcare Conference on Wednesday, July 8, 2015 at 2:30 p.m. Eastern Time at Le Parker Meridien Hotel in New York City.

  3. Show article details.

    Synergy Pharmaceuticals Initiates Second Phase 3 Clinical Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation

    Business Wire – 6:00 AM ET 06/23/2015

    Synergy Pharmaceuticals Inc. (SGYP) announced today the initiation of the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses, taken as a tablet once-a-day, in patients with irritable bowel syndrome with constipation.

  4. Show article details.

    Synergy Pharma's constipation drug succeeds in late-stage study

    Reuters – 7:36 AM ET 06/17/2015

    Synergy Pharmaceuticals Inc (SGYP) said its drug for idiopathic constipation met the main goal in a late-stage trial, sending its shares up 56 percent in premarket trade on Wednesday. Plecanatide, Synergy's lead experimental drug, mimics a hormone that promotes fluid secretion in the gastrointestinal tract, allowing for normal bowel function.

  5. Show article details.

    Synergy Pharma constipation drug succeeds in late-stage study

    Reuters – 6:18 AM ET 06/17/2015

    Synergy Pharmaceuticals Inc (SGYP) said its experimental drug for treating idiopathic constipation was found safe and effective in a late-stage trial. More patients taking the drug, plecanatide, responded to the constipation treatment compared with those on a placebo. Synergy plans to apply for regulatory approval in the fourth quarter.

  6. Show article details.

    Synergy Pharmaceuticals Announces Positive Results in the First Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation (CIC)

    Business Wire – 6:00 AM ET 06/17/2015

    Synergy Pharmaceuticals Inc. (SGYP) today announced positive top-line results from the first of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses, taken as a tablet once-a-day, in 1,346 adult patients with chronic idiopathic constipation.

  7. Show article details.

    U.S. charges four with insider trading in stock offerings

    Reuters – 12:37 PM ET 06/03/2015

    * Criminal, civil charges filed in New Jersey. * Defendants accused of short-selling prior to 14 offerings. By Jonathan Stempel. The owner of a day trading operation and three associates were arrested on Wednesday over an alleged insider trading scheme that generated more than $3.2 million of illegal profit through short-selling in advance of public stock offerings.

  8. Show article details.

    Synergy Pharmaceuticals Reports 2015 First Quarter Results and Business Update

    Business Wire – 4:15 PM ET 05/11/2015

    Synergy Pharmaceuticals Inc. (SGYP), a biopharmaceutical company focused on the development of novel treatments for gastrointestinal diseases and disorders, today reported its financial results and business update for the first quarter ended March 31, 2015.

  9. Show article details.

    Synergy Pharmaceuticals to Present at the UBS Global Healthcare Conference

    Business Wire – 6:00 AM ET 05/04/2015

    Synergy Pharmaceuticals Inc. (SGYP) today announced that its Chairman and Chief Executive Officer, Gary S. Jacob, Ph.D., will present a corporate update at the UBS Global Healthcare Conference on Wednesday May 20th at 12:00pm at the Sheraton New York Times Square Hotel in New York City.

  10. Show article details.

    Chief Scientific Officer of Synergy Pharmaceuticals to Give Keynote Presentation at the 17th Annual TIDES Summit

    Business Wire – 8:16 AM ET 04/30/2015

    Synergy Pharmaceuticals Inc. (SGYP), today announced its Chief Scientific Officer, Kunwar Shailubhai, PhD, MBA, will give a keynote presentation at the 17th Annual TIDES Summit being held May 3-6, 2015 in San Diego, CA. The session titled, “Plecanatide and SP-333, Analogues of Uroguanylin, as Innovative Oral Drugs for Treatment of Gastrointestinal Disorders and Diseases”, will be on Monday, May 4t...

Page:

Today's and Upcoming Events

  • Aug
    10

    SGYP to announce Q2 earnings Unspecified (Unconfirmed)

Past Events (last 90 days)

  • Jun
    8

    Shareholders Meeting

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.